Xbrane's Lucentis biosimilar, for wet AMD and other serious eye conditions, with a US launch planned for 2027.
Carreño discusses oral protein-folding correction for RHO-adRP, early-phase trial end points and genetic eligibility.
An estimated 9.6 million people in the US have diabetic retinopathy, and roughly 1 in 3 patients with diabetes miss annual ...
Eye care providers urged FDA advisers to approve SYD-101, citing myopia’s lifelong risks, compounding gaps and STAR trial ...
Luma, an eye-tracking and assessment tool, helps eye care professionals gain objective insights into visual performance.
A study published in JAMA Ophthalmology 1 reported that spectacle lenses with highly aspherical lenslets (HAL) are safe and ...
In more than 90,000 people across TWO independent cohorts, those with atrial fibrillaion (AF) had a thinner macular ganglion ...
Jordana G. Fein, MD, MS, points to agent selection, payer requirements, and real-world treatment response across 3 retina ...
The milestone moves what Oculis describes as the first genotype-guided registrational trial in DED a step closer to a readout ...
Omur Ucakhan, MD, explains why artificial tears are not interchangeable and how dry eye phenotype should guide formulation ...
Rheumatoid arthritis (RA) is an autoimmune disorder that develops much more frequently in women than men, with a ...
Teprotumumab-trbw (Tepezza; Amgen) has demonstrated clinical benefit in thyroid eye disease (TED), but less is known about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results